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Abstract
Background: Cesarean scar pregnancy (CSP), once a rare entity, is on the rise due because of an increase in the
cesarean section rate worldwide. Currently, there is no standard protocol available for managing CSP. To con-
tribute to the existing literature, this article presents the current authors’ experience with 2 cases of CSP that were
treated successfully with two different modalities. Cases: Case 1: A 34-year-old, gravida 2, para 1, was diagnosed
with a CSP on initial transvaginal ultrasound (TVUS) scan at 6 weeks of gestation. Aspiration of the gestational sac
and a local injection of methotrexate was performed. After 2 weeks, the gestational sac increased in size with
thinning of the CS scar (1 mm), and plateauing of the ß–human chorionic gonadotropin (ß-hCG) occurred. La-
paroscopic excision of the CSP and myometrial repair resulted in resolution. Case 2: A 31-year-old, gravida 3, para
1, achieved pregnancy after a frozen–thawed embryo transfer cycle. A TVUS scan, performed at 6 weeks of
gestation showed a CSP. The patient’s ß-hCG level was 310 mIU/mL. Systemic methotrexate was administered
intramuscularly. The patient’s ß-hCG on days 4 and 7 was 260 and 252, respectively. A repeat TVUS on day 7
showed a resolving gestational sac. A second dose of methotrexate resulted in complete resolution of the CSP.
Results: The treatments (aspiration, methotrexate, and laparoscopic excision for Case 1, and methotrexate for Case
2) enabled resolution of the CSPs of these 2 patients. Conclusions: Various treatment modalities have been
described for managing CSP with varied levels of success. When local injection of methotrexate into the gestational
sac of CSP is unsuccessful, laparoscopic removal is safe and effective. Moreover, in the presence of low levels of
b-hCG, treatment with systemic methotrexate is usually successful. ( J GYNECOL SURG 30:168)
Introduction
Cesarean scar pregnancy (CSP) is a pregnancy occur-ring in the uterine scar of a prior cesarean section. CSP is a
long-term complication of a prior cesarean delivery, and the
numbers of cases reported are increasing every year. This rise
appears to be secondary to increasing awareness and an in-
crease in the cesarean-section rate across the world.1,2 Given
this increase, there seems to be a significant underreporting of
CSP as evidenced by the small number of cases reported in the
United States. The incidence of CSP has been estimated to
range between 1/1800 and 1/2500 of all cesarean deliveries
performed.3,4 CSP constitutes 6.1% of all ectopic pregnancies,
in patients with histories of at least one cesarean delivery.3,5,6
The etiology and pathophysiology of CSP is still under inves-
tigation, and a satisfactory explanation cannot be provided at
this time. However, one of the most-considered pathophysiol-
ogies is that implantation of the embryo into the uterine wall
occurs through an internal dehiscence of the scar or through a
small pathway from the endometrial canal to the scar tissue.7–10
CSP is often misdiagnosed as a cervical ectopic pregnancy,
an incomplete abortion, or a lower intrauterine pregnancy.
For instance, the diagnosis of CSP was missed in 13.6% of
the reported cases.11 This delay in the diagnosis and subse-
quent management can lead to potentially life-threatening
complications.3,8,12,13 Moreover, the overall complications
of different treatment regimens are reported to be as high as
44.1%.11 This indicates the need for a management protocol
with the lowest complication rate and the highest success
rate. A review of the literature revealed that there is no
standard protocol available for managing CSP. To contrib-
ute to the existing literature, the current authors present their
experience with 2 cases of CSP who were treated success-
fully with two different management modalities.
1Department of Obstetrics and Gynecology, Hurley Medical Center, Flint MI.
2Department of Obstetrics and Gynecology and Reproductive Biology, Michigan State University, College of Human Medicine, Flint
Campus, Flint MI.
3Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Hurley Medical Center, Flint MI.
4IVF Michigan PC, Flint and Rochester Hills, MI.
JOURNAL OF GYNECOLOGIC SURGERY
Volume 30, Number 3, 2014
ª Mary Ann Liebert, Inc.
DOI: 10.1089/gyn.2013.0131
168
Cases
Case 1
A 34-year-old Caucasian woman, gravida 2, para 1, pre-
sented for a routine obstetrical transvaginal ultrasound
(TVUS) at 9-weeks of gestation. She had a positive home
pregnancy test after missing a period a few weeks prior. Her
pregnancy had been uneventful other than some mild spot-
ting at the gestational age of 7 weeks for which the patient
did not seek medical attention. She had a prior history of a
low transverse cesarean section 1 year prior, which was
performed after a failed induction of labor. The dating ul-
trasound showed a gestational sac in the cervical canal. A
possibility of cervical ectopic pregnancy versus an incom-
plete abortion was considered. A quantitative assay of her
level of ß-subunit of human chorionic gonadotrophin (ß-
hCG) was 9084 mIU/mL. This ß-hCG 2 days later was
10328 mIU/mL. A second ultrasound (Fig. 1 A and B)
showed a gestational sac with a yolk sac in the cervical
canal, confirming the diagnosis of either a cervical ectopic
pregnancy or a CSP. The patient was offered options of
either undergoing a systemic injection of methotrexate or an
aspiration of the pregnancy, followed by local injection of
methotrexate. She chose the latter option. The next day, the
patient underwent TVUS-guided aspiration of the gesta-
tional sac followed by a local injection of 77.5 mg (50 mg/m2)
of methotrexate. She tolerated the procedure well and went
home on the same day. TVUS scanning performed 1 week
after treatment showed a collapse of the gestational sac (Fig.
2). Repeat testing of her levels of ß-hCG at days 4, 6, 7, 10,
13, and 17 after the procedure were 16911, 14420, 11502,
8653, 8196, 7426 mIU/mL, respectively. Plateauing of ß-hCG
levels was observed. A repeat TVUS at that time showed
reaccumulated fluid in the gestational sac with a yolk sac
located in the CS scar (Fig. 3). The myometrium of the CS
scar was very thin over the gestational sac (1 mm). The patient
was advised that the best treatment option was to undergo
surgery to prevent a possible rupture of the CSP. Diagnostic
and operative laparoscopy with a possible laparotomy was
arranged. During laparoscopy, it was observed that the bladder
had adhered to the lower uterine segment over the prior CS
scar (Fig. 4). A bladder flap was created carefully and the
cesarean scar containing the pregnancy was exposed. Twenty
mL of vasopressin was injected circumferentially in and
around the pregnancy to ensure hemostasis. A small vertical
incision was made over the pregnancy and the products of
conception were removed, using forceps and scissors (Fig. 5 A
and B). Four figure-8 stitches, using 2-0 Vicryl, were placed to
close the uterine defect (Fig. 6). Diluted indigo carmine dye
was injected through a Foley catheter to ensure that her
bladder was intact. The patient recovered from the procedure
well, and she was discharged to go home the same day. Her ß-
hCG levels were normal after 1 month.
Case 2
A 31-year-old Caucasian woman, gravida 3, para 1, achieved
pregnancy via in-vitro fertilization frozen embryo transfer
FIG. 1. Two-dimensional transvaginal ultrasound (sagittal
view). Gestational sac and yolk sac seen at the region of
internal os (arrow).
FIG. 2. Two-dimensional transvaginal ultrasound (sagittal
view): A collapsed gestational sac was noted (arrow) 1 week
post aspiration and intragestational methotrexate.
FIG. 3. Two-dimensional transvaginal ultrasound (sagittal
view). Reaccumulation of fluid in the gestational sac and
reappearance of yolk sac (arrow) at the region of the ce-
sarean scar noted 2 weeks post aspiration and intragesta-
tional methotrexate.
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(IVF-FET) with an estrogen- and progesterone-stimulated
cycle. Two blastocysts were transferred without any com-
plications. This patient had a prior history of a successful
IVF pregnancy (for male-factor infertility) that was deliv-
ered at term via a low transverse cesarean section 2.5 years
ago. Her first quantitative ß-hCG level 2 weeks post IVF-
FET was 246 mIU/mL. She had brownish spotting and mild
cramping 15 days after the IVF-FET; this symptom subsided
in 2 days. A repeat ß-HCG test in another 2 weeks showed a
level of 310 mIU/mL. TVUS was performed, which showed a
gestational sac in the cesarean scar with an otherwise normal
uterine cavity. (Fig. 7 A and B). Only a small gestational sac
and yolk sac were noted, but no fetal pole was seen. Various
treatment modalities were discussed with the patient, and she
chose systemic methotrexate therapy. She was given 113.5 mg
(50 mg/m2) of methotrexate intramuscularly (IM) the next
day. Post methotrexate, this patient started having vaginal
bleeding for 6 days. Her ß-HCG levels on days 4 and 7 were
260 and 252 mIU/mL, respectively. A repeat TVUS on day 7
showed an empty uterus (Fig. 8A and B). However, a decision
was made to administer a second dose of methotrexate sec-
ondary to her plateauing ß-HCG levels. She was given
113.5 mg (50 mg/m2) of methotrexate IM again. Her ß-HCG
levels on days 4 and 7 were 83 and 51 mIU/mL, respectively.
Her ß-HCG levels normalized within 1 month of adminis-
tration of the first dose of methotrexate.
Results
The treatments (aspiration, methotrexate, and laparo-
scopic excision for Case 1, and methotrexate for Case 2)
enabled resolution of the CSPs of these 2 patients.
Discussion
CSP represents a diagnostic and management dilemma. De-
layed diagnosis and management can lead to life-threatening
complications.3,8,11,13 The increasing rate of cesarean de-
liveries, a higher index of suspicion secondary to mounting
awareness, and better diagnostic studies such as high-frequency
TVUS can possibly explain the recent increase of cases
described in the literature.3,5,14
Many management modalities have been described in the
literature. In a review article, Timor-Tritsch et al. describe a
combined modality with the lowest complication rate that was
based on a review of literature and their own experience.11
These researchers recommended local intragestational and
FIG. 4. Bladder adhered to the lower uterine segment over
the prior cesarean section scar (arrow).
FIG. 5. (A) After dissecting bladder flap, the ectopic
gestation (arrow) is being manipulated by grasping forceps.
(B) Removal of ectopic gestation in progress (arrow).
FIG. 6. Closure of uterine defect (arrow).
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systemic methotrexate therapy; this was reported to produce a
complication rate as low as 5.3% in the cases that were
treated. The downside of this treatment is a longer return to
baseline and a lengthy follow-up, which is up to a minimum
of 3 months. This might not be suitable for a noncompliant
patient or one who will not be able to come back for frequent
follow-up visits. In Case 1, a local injection of methotrexate
and gestational sac aspiration resulted in plateauing of the
patient’s ß-hCG levels. Reaccumulation of fluid in the gesta-
tional sac and marked thinning of the ceserean scar predis-
posed the CSP to a high risk of impending rupture; hence,
laparoscopic surgery was performed without any complica-
tions and a quick return of ß-hCG to baseline was observed.
Vial et al.15 has described two distinct types of CSP: (1)
Superficial implantation in the scar with progression of the
pregnancy toward the uterine cavity; and (2) deeper implan-
tation in a cesarean-scar defect with pregnancy progression
outside the uterine cavity. One of the surgical treatments with
the lowest complication rate described was hysteroscopic
resection (14.7%).11 A literature review showed that this
modality might be one of the best available surgical man-
agements for a CSP that projects inside the uterine cavity,
because this approach can enable direct visualization of the
vessels and subsequent coagulation, as the CSP is resected
with a resectoscope.16–24 However, hysteroscopic resection
might not be the best choice when the pregnancy is implanted
deeper in the cesarean scar and tends to progress toward the
bladder. In case 1, the TVUS revealed a very thin myome-
trium of 1–2 mm overlying the scar and a CSP in close
proximity to the bladder. The decision was made to perform
laparoscopy in order to dissect the bladder away from the
CSP under direct visualization and hence reduce the risk of
injury. This would have been very challenging if a hystero-
scopic resection had been performed. This concept has also
been supported by other researchers.10,25 However, it remains
undisputed that both operative laparoscopy and hysteroscopy
are heavily dependent on a surgeon’s expertise. Systemic
methotrexate is a modality with one of the highest compli-
cation rates (i.e., 62.1%).11 The literature review also showed
that, if ß-hCG was < 5000 and the gestational age was < 8
weeks, the chance of success was higher.3,5–7,26 In the ex-
perience of the current authors, Case 2 was diagnosed very
FIG. 8. (A) Two-dimensional (2D) transvaginal ultra-
sound (TVUS; sagittal view) showing resolution of cesarean
scar ectopic pregnancy 1 week post systemic methotrexate.
(B) 2D TVUS (transverse view). Resolution of cesarean scar
ectopic pregnancy 1 week post systemic methotrexate.
FIG. 7. (A) Two-dimensional (2D) transvaginal ultra-
sound (TVUS; sagittal view) thickened endometrial stripe.
No pregnancy sac was identified. (B) 2D TVUS (transverse
view). Small gestational sac and yolk sac at the region of the
cesarean scar (arrow).
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early in her pregnancy secondary to close follow-up after her
IVF-FET. She was treated with 2 doses of systemic metho-
trexate 1 week apart, which resulted in a prompt resolution
without any complications (1 month).
Conclusions
An earlier diagnosis leads to a better outcome. Various
treatment modalities have been described for managing CSP,
with varied levels of success, but the optimal management
and a standardized protocol remains to be determined. The
goal of therapy should be preservation of fertility, reduction
of life-threatening complications, and maintaining the pa-
tient’s quality of life. In the current author’s experience, when
local injection of methotrexate in the gestational sac is not
successful, laparoscopic removal of CSP is safe and effective.
In the presence of low levels of b-hCG, treatment with sys-
temic methotrexate is usually successful.
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